Home » News » Industry news » IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

Views: 0     Author: Site Editor     Publish Time: 2025-03-20      Origin: Site

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

TOKYO, March 24, 2025--(BUSINESS WIRE)--IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations on April 9-11.

"IFF Pharma Solutions is committed to redefining drug delivery through material science innovation," said Frank Zhao, commercial leader, IFF Pharma Solutions, Asia Pacific. "At CPHI Japan, we will showcase technologies designed to elevate patient outcomes while streamlining pharmaceutical production."

As a global leading pharmaceutical excipient partner, IFF Pharma Solutions will highlight some of its latest innovations, including:

Oral Disintegrating Tablet (ODT) Solutions

  • The ODT market is expanding rapidly, requiring tablets that dissolve quickly for easy administration to children and elderly patients. Incorporating super disintegrants into ODT formulations is essential, as these agents enhance dissolution speed and improve patient compliance. Ac-Di-Sol®, a leading super disintegrant, offers equivalent disintegration efficacy to polyvinylpolypyrrolidone (PVPP).


  • METHOCEL™ Hydroxypropyl methylcellulose (HPMC): Enables consistent and controlled delivery of medication, enhancing therapeutic efficacy and patient compliance through customizable HPMC.

  • ETHOCEL™ Ethylcellulose: Water-resistant barrier coatings for targeted drug delivery and taste masking in modified-release tablets.

  • POLYOX™ Polyethylene Oxide: High-swell matrices for osmotic delivery and abuse-deterrent systems, supporting osmotic pump technology and modified-release matrix formulations.

Low-Nitrite Solutions

  • As a low-nitrite microcrystalline cellulose solution, Avicel® PH LN reduces nitrosamine formation risks in oral solid dosages, ensuring compliance with Japan’s stringent regulatory standards.

  • IFF Pharma Solutions expands its low-nitrite excipient portfolio by introducing Low Nitrite METHOCEL™, tailored to help mitigate the risk of nitrosamine formation in drugs.

Combining its deep expertise in excipients, innovation capabilities, and regulatory services, IFF Pharma Solutions offers an integrated solutions platform for customer support at every step of their formulation journeys. To learn more about our broad portfolio and proven expertise.


Phone:
+86-21-69895597
Address:
Rm 327,3rd Floor D Zone,No.33,Lianxin Rd.,Liantang Town,Qingpu Dist.Shanghai China
About Us
Tocosynth is the Chinese dosmetic susidiary company of Tocopharm,who mainly R&D and manufacturing chemicals raw materials based in Shanghai,China.Our company was established in 2012.
Subscribe
Sign up for our newsletter to receive the latest news.


Copryright © 2023 Tocopharm(Shanghai) Co., Ltd. Technology by Leadong.Sitemap